[Funding alert] Belgium-based Cognivia Secures €15.5Million in Funding

Strategic investments have been made by Vesalius Biocapital IV, SFPIM (Société Fédérale de Participations et d'Investissement), and WE (Wallonie Entreprendre) to support Cognivia's objective to "quantify the power of the mind" in order to expedite and improve drug development initiatives.

With this financial infusion, Cognivia will be able to quickly create novel treatments for patients around the world by using its predictive clinical trial solutions, which identify the correlation between a patient's characteristics and behaviours.

Read also - Poland-based bValue Secures €90Million in Funding

The solutions offered by Cognivia focus on important issues including medication adherence in clinical trials and the placebo response, which have previously presented major obstacles to drug development.

The mathematical understanding of patients as unique individuals is being pioneered by Cognivia, unlike any other, and these insights are being integrated into clinical trial data analysis and/or patient engagement strategy optimisation.

PlacebellTM, for example, uses predictive algorithms to lessen the adverse effects of the placebo response, increasing the study power of clinical trials and leading to higher success rates and shorter clinical trial durations and expenses.

Olivier Houben, Partner at Vesalius Biocapital said, "We are thrilled to announce Cognivia as the inaugural investment of our fund IV, which focuses on HealthTech and biopharma companies at the forefront of innovation transforming healthcare. We eagerly anticipate partnering with them throughout their commercialization and growth stages.".

Dominique Demolle, CEO/Co-founder of Cognivia said, "Cognivia's strategic alliances with Vesalius Biocapital IV, SFPIM and WE signify a pivotal moment in our quest to transform the industry through a unique blend of decades-long industry experience and advanced AI, With this investment and the welcomed addition of new members to our operational team and Company Board and Strategic Advisory Committee, to be announced soon, we are poised to accelerate our efforts in delivering groundbreaking approaches that empower clinicians, researchers and industries to make informed, data-driven decisions, ultimately enhancing outcomes for patients and stakeholders worldwide."

About Cognivia

Cognivia is the first and only business to improve therapeutic efficacy measurement in clinical trials and beyond by fusing artificial intelligence (AI) and machine learning (ML) with quantification of patient psychology.

It technologies use predictive machine learning (ML)-powered algorithms to forecast patient behaviour and treatment response in clinical trials. These algorithms are based on a quantitative understanding of the psychological traits, expectations, and beliefs of patients, which is gathered through their own and specially designed questionnaires.